Literature DB >> 18376144

MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.

Adly Yacoub1, Hossein Hamed, Luni Emdad, Wagner Dos Santos, Pankaj Gupta, William C Broaddus, Viswanathan Ramakrishnan, Devanand Sarkar, Khalid Shah, David T Curiel, Steven Grant, Paul B Fisher, Paul Dent.   

Abstract

Melanoma differentiation associated gene-7/interleukin 24 (mda-7/IL-24) is a cytokine displaying selective apoptosis-inducing activity in tumors, including glioblastoma (GBM), without damaging normal cells. The present studies focused on defining whether an adenovirus expressing MDA-7/IL-24, Ad.mda-7, infused into pre-formed invasive primary human GBM tumors growing in athymic mouse brains altered tumor cell growth and animal survival, and whether Ad.mda-7 radiosensitized GBM cells and enhanced the survival benefit of irradiation. Ad.mda-7 directly radiosensitized glioma cells in vitro in a JNK1-3- and caspase 9-dependent fashion and demonstrated bystander-effect killing and radiosensitization of GBM cells when primary human astrocytes were infected with Ad.mda-7. Infusion of Ad.mda-7 into pre-formed glioma tumors caused a rapid decrease in proliferation and blood vessel density and an increase in cell killing. Irradiation of Ad.mda-7 infected tumors enhanced cell death. Cell killing correlated with pro-caspase 3 cleavage, enhanced phosphorylation of JNK1-3 and reduced phosphorylation of ERK1/2. Ad.mda-7 enhanced the survival of animals implanted with GBM6 and GBM12 tumors, and significantly increased the survival benefit of irradiation in animals bearing GBM12 tumors. Ad.mda-7 toxicity was evident against CD133+ and CD133- GBM cells; upon tumor re-growth approximately 70-100 days after virus infusion, the relative CD133+ level within the tumor was profoundly reduced with lower Ki67 reactivity and increased beta-galactosidase staining. Infusion of Ad.mda-7 into an immune competent rat brain did not cause normal tissue toxicity 1-4 weeks after infusion using T1 and T2 weighted MRI and H&E staining. Our data demonstrate that Ad.mda-7 prolongs the survival of animals bearing GBM tumors and does so through multiple mechanisms including direct tumor cell killing and selection for surviving cells that are more differentiated and potentially displaying a putatively senescent phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376144     DOI: 10.4161/cbt.7.6.5928

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  30 in total

1.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Authors:  Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 2.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.

Authors:  Anjan K Pradhan; Praveen Bhoopathi; Sarmistha Talukdar; Danielle Scheunemann; Devanand Sarkar; Webster K Cavenee; Swadesh K Das; Luni Emdad; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-06       Impact factor: 11.205

4.  Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.

Authors:  Timothy P Kegelman; Bainan Wu; Swadesh K Das; Sarmistha Talukdar; Jason M Beckta; Bin Hu; Luni Emdad; Kristoffer Valerie; Devanand Sarkar; Frank B Furnari; Webster K Cavenee; Jun Wei; Angela Purves; Surya K De; Maurizio Pellecchia; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-23       Impact factor: 11.205

5.  Astrocyte elevated gene-1: a novel target for human glioma therapy.

Authors:  Luni Emdad; Devanand Sarkar; Seok-Geun Lee; Zhao Zhong Su; Byoung Kwon Yoo; Rupesh Dash; Adly Yacoub; Christine E Fuller; Khalid Shah; Paul Dent; Jeffrey N Bruce; Paul B Fisher
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

6.  External irradiation models for intracranial 9L glioma studies.

Authors:  Sandrine Vinchon-Petit; Delphine Jarnet; Eric Jadaud; Loïc Feuvret; Emmanuel Garcion; Philippe Menei
Journal:  J Exp Clin Cancer Res       Date:  2010-11-08

7.  Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.

Authors:  Adelaide Greco; Altomare Di Benedetto; Candace M Howard; Sarah Kelly; Rounak Nande; Yulia Dementieva; Michele Miranda; Arturo Brunetti; Marco Salvatore; Luigi Claudio; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Pier P Claudio
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

8.  MRI assessment of experimental gliomas using 17.6 T.

Authors:  Marc A Schwarz; Mirko Pham; Xavier Helluy; Arnd Doerfler; Tobias Engelhorn
Journal:  Neuroradiology       Date:  2013-03-10       Impact factor: 2.804

9.  Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24.

Authors:  Sujit K Bhutia; Swadesh K Das; Belal Azab; Mitchell E Menezes; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Int J Cancer       Date:  2013-07-06       Impact factor: 7.396

10.  Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.

Authors:  Hossein A Hamed; Adly Yacoub; Margaret A Park; Kellie Archer; Swadesh K Das; Devanand Sarkar; Steven Grant; Paul B Fisher; Paul Dent
Journal:  Mol Pharmacol       Date:  2013-05-09       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.